VistaGen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2014; filed February 17, 2015. The company is a clinical-stage biopharmaceutical developer with no approved products and no current revenue.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2014 | Nine months ended Dec. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $445,400 | $1,476,600 | $551,300; $1,916,100 |
| General and administrative expense | $671,300 | $2,024,600 | $897,000; $2,047,500 |
| Net income (loss) | $(1,090,300) | $(7,664,500) | $131,000; $(1,143,100) |
| Operating cash flow | $(1,874,400) for nine months | $(1,658,900) for nine months |
Quarterly operating expenses fell about 23% year over year; nine-month operating expenses fell about 12%. Nine-month net loss widened substantially, primarily reflecting a $2.371 million debt-extinguishment loss and higher interest expense, partly offset by a $528,300 non-cash gain from revaluing warrant liabilities. Interest expense, net was $2.183 million versus $1.001 million for the prior nine months. These items materially affect reported earnings.
At December 31, 2014, cash and cash equivalents were only $13,200; current assets were $75,500 and current liabilities $10.764 million. Total assets were $259,400, total liabilities $18.043 million, and accumulated deficit $78.301 million. The filing reports approximately $11.8 million of outstanding indebtedness by principal amount; approximately $7.2 million was due or expected to become due within 12 months absent restructuring or conversion. Approximately $2.3 million of unsecured notes were past due and payable on demand. The filing does not provide a meaningful gross margin because there was no revenue.
Cash provided by financing activities was $1.888 million for the nine months, primarily from unit sales; cash used in investing activities was zero. After quarter-end, the company raised an additional $768,500 through unit sales through February 13, 2015. The company said expected cash expenditures were approximately $7.5 million over the next 12 months and estimated it would need $10–15 million of financing to execute its plan if the Autilion financing did not close.
Material changes and business developments
- Quarterly R&D expense declined to $445,400 from $551,300; nine-month R&D expense declined to $1.477 million from $1.916 million. Management cited reduced research spending and lower technology-license costs, among other changes.
- Quarterly G&A expense declined to $671,300 from $897,000, partly due to lower stock-based compensation and no comparable prior-year warrant-modification expense. For the nine months, G&A was nearly flat at $2.025 million versus $2.048 million; increased legal and professional costs included a $102,000 write-off associated with a withdrawn public-offering registration statement.
- In August 2014, the company effected a 1-for-20 reverse stock split. The filing reports 1,473,528 common shares issued and outstanding as of February 13, 2015.
- On February 10, 2015, VistaGen entered a CRADA with the NIMH for an NIH-sponsored Phase 2 AV-101 study in major depressive disorder. The study was expected to begin in the first half of 2015 and finish by year-end; it was described as NIH-funded.
Outlook, risks and unusual items
- Going concern: Management stated the company lacked sufficient cash at December 31, 2014 to fund planned operations. The filing describes substantial doubt about continued operations without significant additional financing. Auditors had previously expressed substantial doubt in the fiscal 2014 annual report.
- Financing uncertainty: Autilion AG remained in default under an agreement to purchase $36 million of shares; management said there was substantial doubt that it would close. The company may need alternative financing, which may not be available on acceptable terms or at all.
- Near-term maturities: Approximately $4.0 million of amended 2013 and 2014 unit notes, including accrued interest, matured March 31, 2015. Holders could request cash repayment rather than conversion. The company also warned it might need to repay senior notes unless it reached a new agreement with Platinum.
- Potential dilution and control: Financing through equity or convertible debt could significantly dilute existing holders. The filing also said a sufficiently large Autilion financing could give Autilion control of more than 50% of common shares.
- Operating and development risks: AV-101 remained in development, and clinical efficacy and safety were not established by the filing. Drug-rescue programs depend on validation of the company’s CardioSafe 3D and LiverSafe 3D platforms; management disclosed that LiverSafe 3D was not fully validated and CardioSafe 3D studies had not undergone external validation.
- Management commentary: To conserve cash, senior executives voluntarily accepted salary reductions; some unpaid compensation was accrued. Management expected losses and negative operating cash flows to continue. No quantified earnings or revenue guidance was provided.
- The company reported effective disclosure controls, no material change in internal control over financial reporting, no material legal proceedings, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether the company secured sufficient financing after the reported $768,500 post-quarter unit sale, and how proceeds compare with the stated $10–15 million need.
- Whether the March 31, 2015 unit-note maturities were repaid, converted, or further amended, and the status of past-due notes and Platinum senior debt.
- Whether Autilion’s default was resolved or alternative financing obtained, including resulting dilution and any change in control.
- Whether the NIH-sponsored AV-101 Phase 2 study began on schedule, and its actual funding, enrollment, timing, and results.
- Whether cash runway, operating spending, and accrued unpaid compensation changed materially after December 31, 2014.